Brief: I-Mab announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at Esmo Congress 2022

NovaBridge Biosciences

06/09/2022 13:28

Sept 6 (Reuters) - I-Mab  IMAB.O :
    * I-MAB ANNOUNCES ORAL PRESENTATION OF PHASE 2 CLINICAL DATA
OF
CD47 ANTIBODY LEMZOPARLIMAB AT ESMO CONGRESS 2022

Source text for Eikon:  ID:nPnbJ5MMXa 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))